SLC2A13 encodes a proton-myo-inositol cotransporter located on the plasma membrane and intracellular compartments 1. It mediates symport of myo-inositol and related stereoisomers coupled to proton gradients, participating in cellular inositol homeostasis and signaling. Functionally, SLC2A13 associates with γ-secretase and regulates amyloid-β (Aβ) production; silencing SLC2A13 reduces Aβ secretion dose-dependently, while overexpression increases Aβ40 generation, suggesting a role in Alzheimer's disease pathogenesis 2. In cancer biology, SLC2A13 is enriched in sphere-forming cells from oral squamous cell carcinoma and may serve as a cancer stem cell marker 3. In acute myeloid leukemia, high SLC2A13 expression associates with improved prognosis 4. Genetically, SLC2A13 variants show caffeine-gene interactions influencing Parkinson's disease risk 5, and rare variants are enriched in early-onset Parkinson's disease 6. Specific SLC2A13 polymorphisms (rs2242367) associate with protracted disease courses in progressive supranuclear palsy, potentially conferring slower clinical progression 78. These findings position SLC2A13 as a multifunctional transporter relevant to neurodegenerative and neoplastic diseases.